This inventor holds 1 USPTO granted patent. Top assignee: Ligand Pharmaceuticals, Inc.. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Innovations of Mani Neelakandha in Androgen Receptor Modulation
Introduction
Mani Neelakandha is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of androgen receptor modulator compounds. His work focuses on creating non-steroidal compounds that can effectively modulate processes mediated by steroid receptors.
Latest Patents
Neelakandha holds a patent for "Androgen receptor modulator compounds and methods." This patent encompasses compounds, pharmaceutical compositions, and methods for modulating processes mediated by steroid receptors. Specifically, it details the preparation and methods of use for non-steroidal compounds that act as agonists, partial agonists, and antagonists for the androgen receptor (AR). The patent also describes methods for making and using critical intermediates, including a stereoselective synthetic route to intermediates for the AR modulators.
Career Highlights
Mani Neelakandha is currently associated with Ligand Pharmaceuticals, Inc., where he continues to innovate in the field of drug development. His expertise in androgen receptor modulation has positioned him as a key player in advancing therapeutic options for various medical conditions.
Collaborations
Neelakandha has collaborated with several professionals in his field, including Robert Higuchi and Kristen Lee Arienti. These collaborations have further enhanced the research and development efforts at Ligand Pharmaceuticals.
Conclusion
Mani Neelakandha's contributions to the field of pharmaceutical sciences, particularly through his patent on androgen receptor modulators, highlight his innovative spirit and dedication to advancing medical research. His work continues to influence the development of new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
